The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines

Molecular Biology Reports

Volumn 41, Issue 12, 2014, Pages 8031-8036

  Arman, Kaifee ^a   Ergün, Sercan ^a   Temiz, Ebru ^a   Öztuzcu, Serdar ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Cancer cell line; Caspase 3; Caspase 8; HER2 ErbB2

Indexed keywords

CASPASE 3; CASPASE 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER CELL CULTURE; CELL SURVIVAL; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; GASTRIC CANCER CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; LUNG CANCER CELL LINE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; UPREGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; TUMOR CELL LINE;

APOPTOSIS; CASPASE 3; CASPASE 8; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2;

EID: 84926658570     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-014-3700-x     Document Type: Article

References (40)

1. Olayioye MA et al (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159–3167
2. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357(1):39–51
3. Slamon DJ et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
4. Meric-Bernstam F, Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12(21):6326–6330
5. Slamon DJ et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712
6. Ward SG, Finan P (2003) Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 3(4):426–434
7. Chang F et al (2003) Involvement of PI3 K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17(3):590–603
8. Yu D, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19(53):6115–6121
9. Yu DH, Hung MC (1991) Expression of activated rat neu oncogene is sufficient to induce experimental metastasis in 3T3 cells. Oncogene 6(11):1991–1996
10. Yu D et al (1998) Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2(5):581–591
11. Carpenter RL, Lo HW (2013) Regulation of apoptosis by HER2 in breast cancer. J Carcinog Mutagen S7:003. doi:10.4172/2157-2518.S7-003
12. Jiang X, Wang X (2004) Cytochrome C-mediated apoptosis. Annu Rev Biochem 73:87–106
13. Ergun S et al (2014) Expression patterns of miR-221 and its target Caspase-3 in different cancer cell lines. Mol Biol Rep 41(9):5877–5881
14. Foster FM et al (2009) Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 11(3):R41
15. Yu D et al (1998) Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16(16):2087–2094
16. Pietras RJ et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10(12):2435–2446
17. Pauletti G et al (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13(1):63–72
18. Pegram MD et al (1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15(5):537–547
19. Disis ML, Cheever MA (1997) HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv Cancer Res 71:343–371
20. Mitri Z, Constantine T, O’Regan R (2012) The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193
21. Yu D et al (1996) Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13(6):1359–1365
22. Wang XF et al (2010) Alpha-tocopheryl succinate induces apoptosis in erbB2-expressing breast cancer cell via NF-kappaB pathway. Acta Pharmacol Sin 31(12):1604–1610
23. Mathiasen IS, Lademann U, Jaattela M (1999) Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59(19):4848–4856
24. Schneider PM et al (1989) Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49(18):4968–4971
25. Weiner DB et al (1990) Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50(2):421–425
26. Shi D et al (1992) Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog 5(3):213–218
27. Chiang YY et al (2014) Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis-inducing factor in non-small cell lung cancer. Oncol Rep 31(2):597–604
28. Ren SH, Wang JW, Zhang L (2005) Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells. Zhonghua Yi Xue Za Zhi 85(22):1530–1534
29. Ren SH et al (2005) Effect of RNAi-mediated gene silencing of C-erbB-2 on proliferation of lung adenocarcinoma cell line calu-3. Ai Zheng 24(10):1173–1178
30. Siampanopoulou M et al (2013) Profiling serum HER-2/NEU in prostate cancer. Hippokratia 17(2):108–112
31. Zhang JK et al (2010) Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications. Nan Fang Yi Ke Da Xue Xue Bao 30(2):326–328
32. Potti A et al (2003) HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 23(3B):2671–2674
33. Xian ZH et al (2005) Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol 58(5):500–503
34. Yokota J et al (1988) Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2(3):283–287
35. D’Emilia J et al (1989) Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene 4(10):1233–1239
36. Zhang DX et al (2010) Potent inhibition of human gastric cancer by HER2-directed induction of apoptosis with anti-HER2 antibody and caspase-3 fusion protein. Gut 59(3):292–299
37. Movagharnejad K et al (2013) HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma. Int J Mol Cell Med 2(4):199–203
38. Mitra AB et al (1994) ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 54(3):637–639
39. Shen L et al (2008) E1A inhibits the proliferation of human cervical cancer cells (HeLa cells) by apoptosis induction through activation of HER-2/Neu/Caspase-3 pathway. Med Oncol 25(2):222–228
40. Ndubisi B et al (1997) The prognostic value of HER-2/neu oncogene in cervical cancer. Ann Clin Lab Sci 27(6):396–401